Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.

Item

http://www.wikidata.org/entity/Q36672633

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.

@ast

Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.

@en

type

Item

label

Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.

@ast

Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.

@en

prefLabel

Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.

@ast

Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.

@en

P1476

Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.

@en

P2093

Alan P Lyss

http://www.w3.org/2001/XMLSchema#string

Donald W Northfelt

http://www.w3.org/2001/XMLSchema#string

Edith A Perez

http://www.w3.org/2001/XMLSchema#string

Heshan Liu

http://www.w3.org/2001/XMLSchema#string

Jacob B Allred

http://www.w3.org/2001/XMLSchema#string

Mark W Rodacker

http://www.w3.org/2001/XMLSchema#string

North Central Cancer Treatment Group

http://www.w3.org/2001/XMLSchema#string

Timothy J Hobday

http://www.w3.org/2001/XMLSchema#string

Tom R Fitch

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data.

Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.

Microtubule-targeted anticancer agents and apoptosis.

Microvascular permeability of normal and neoplastic tissues.

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting.

P304

167-171

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/COC.0B013E31826E0550

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23211220

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3593738

http://www.w3.org/2001/XMLSchema#string